LIDOCAINE HYDROCHLORIDE INJECTION SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LIDOCAINE HYDROCHLORIDE

Pieejams no:

LABORATOIRE AGUETTANT

ATĶ kods:

N01BB02

SNN (starptautisko nepatentēto nosaukumu):

LIDOCAINE

Deva:

10MG

Zāļu forma:

SOLUTION

Kompozīcija:

LIDOCAINE HYDROCHLORIDE 10MG

Ievadīšanas:

BLOCK/INFILTRATION

Vienības iepakojumā:

15G/50G

Receptes veids:

Ethical

Ārstniecības joma:

LOCAL ANESTHETICS

Produktu pārskats:

Active ingredient group (AIG) number: 0101280004; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-06-17

Produkta apraksts

PRESCRIBING INFORMATION
LIDOCAINE HYDROCHLORIDE INJECTION
1% Lidocaine hydrochloride (10 mg/mL)
2% Lidocaine hydrochloride (20 mg/mL)
House Standard
Local Anesthetic
Laboratoire Aguettant
1, rue Alexander Fleming
69007 Lyon
France
Imported to Canada by :
CGF Pharmatech Inc.
3516, Griffith Street, Montreal, Qc, H4T 1A7
Date of Preparation:
16-06-2020
Control No: 229599
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................
3
CONTRAINDICATIONS
......................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................
4
ADVERSE REACTIONS
....................................................................................................
10
DRUG INTERACTIONS
....................................................................................................
12
DOSAGE AND ADMINISTRATION
................................................................................
15
OVERDOSAGE
...................................................................................................................
19
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 20
STORAGE AND STABILITY
............................................................................................
22
SPECIAL HANDLING INSTRUCTIONS
..........................................................................
22
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 23
PART II: SCIENTIFIC INFORMATION
...............................................................................
25
PHARMACEUTICAL INFORMATION
.............................................................